San Diego, CA, United States of America

Scott Charles Potter

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Scott Charles Potter: Innovator in Therapeutic Antibodies

Introduction

Scott Charles Potter is an inventor based in the United States, known for his contributions to the field of therapeutic antibodies. His work focuses on developing innovative solutions for treating various diseases, showcasing his commitment to advancing medical science.

Latest Patents

Scott Charles Potter holds a notable patent titled "Cd200r Agonist Antibodies And Uses Thereof." This invention relates to anti-human CD200R agonist antibodies and their applications in treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), graft-versus-host disease (GvHD), and psoriasis. Although he has 1 patents, his work in this area is significant.

Career Highlights

Throughout his career, Scott Charles Potter has demonstrated a strong focus on therapeutic innovations. His research has the potential to impact the treatment landscape for several chronic conditions, highlighting his role as a forward-thinking inventor in the medical field.

Collaborations

Scott has collaborated with notable colleagues, including Stephen John Demarest and Anja Koester. These partnerships have likely contributed to the development and refinement of his innovative ideas.

Conclusion

Scott Charles Potter is a dedicated inventor whose work in therapeutic antibodies aims to address critical health challenges. His contributions to the field reflect a commitment to improving patient outcomes through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…